Cardiff Oncology（納斯達克股票代碼：CRDF）報告季度每股虧損$(0.21)，優於分析師一致預期的$(0.24)，增長了12.5%。與去年同期持平。公司報告季度銷售額為$151.00千，優於分析師一致預期的$94.17千，增長了60.35%。與去年同期的銷售額$156.00千相比下降了3.21%。

以上內容來自Benzinga Earnings專欄，原文如下：

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 12.5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $151.00 thousand which beat the analyst consensus estimate of $94.17 thousand by 60.35 percent. This is a 3.21 percent decrease over sales of $156.00 thousand the same period last year.